ChemicalBook > CAS DataBase List > Alemtuzumab

Alemtuzumab

Product Name: Alemtuzumab
CAS No.: 216503-57-0
Chemical Name: Alemtuzumab
Synonyms: D02802;MabCampath;Alemtuzumab;Campath (tn);Alemtuzumab (usan/inn);Research Grade Alemtuzumab;Research Grade Alemtuzumab(DHD95101)
CBNumber: CB91216036
Formula Weight: 0
MOL File: Mol file

Less

Alemtuzumab Property

form: Liquid
color: Colorless to light yellow

Less

Safety

Hazardous Substances Data: 216503-57-0(Hazardous Substances Data)

Less

Hazard and Precautionary Statements (GHS)

Less

N-Bromosuccinimide Price

American Custom Chemicals Corporation

Product number: ATB0010216
Product name: ALEMTUZUMAB
Purity: 95.00%
Packaging: 5MG
Price: $501.07
Updated: 2021/12/16

Biosynth Carbosynth

Product number: BA165581
Product name: Alemtuzumab
Packaging: 1mg
Price: $550
Updated: 2021/12/16

Less

Alemtuzumab Chemical Properties,Usage,Production

Description

Alemtuzumab was first introduced in the US for the treatment of B-cell chronic lymphocytic leukemia (CLL) in patients who have been treated with alkylating agents and have failed fludarabine therapy. Alemtuzumab is a humanized monoclonal antibody of the IgG1 isotype specific for the glycoprotein CD52 expressed on the cell surface of over 95% of normal and malignant B and T lymphocytes and monocytes. It was genetically engineered by adding six hypervariable regions from the heavy-chain and light-chain variable domains of an IgG2a rat monoclonal antibody onto a human IgG1 immunoglobulin molecule. The exact mechanism of action of alemtuzumab is unknown but the antibody probably causes the lysis of lymphocytes via complement fixation and antibody-dependent cytotoxicity. In a phase III clinical trial with 93 fiudarabine-resistant CLL patients, treatment with alemtuzumab gave a positive response in 31 patients with 2 complete remissions and 29 partial remissions. This study demonstrated a higher response rate in patients having malignancy confined to the blood and bone marrow. Alemtuzumab does not seem to penetrate well into solid tissues and it was found to be concentrated in the blood which seems to correlate with the fact that it appears to be inefficient against tumor cells from lymph nodes and extranodal masses. The half-life of the antibody ranged between 23 and 30 hours. Premedication with acetaminophen and diphenhydramine is effective in reducing infusion-related reactions such as fevers, rigors, rash, nausea or hypotension. The most significant adverse effect is lymphopenia resulting in increased risk of opportunistic infections. As a consequence, prophylactic treatment with antibiotics is recommended for patients under alemtuzumab therapy.

Originator

Cambridge University (UK)

Uses

Antineoplastic (monoclonal antibody).

brand name

Campath (Boehringer Ingelheim KG, Germany).

General Description

Alemtuzumab (Campath) is humanized MAb (Campath-1H)that is directed against the 21- to 28-kDa cell surface glycoproteinCD52. CD52 is expressed on the surface of normaland malignant B and T lymphocytes, NK cells, monocytes,macrophages, and tissues of the male reproductive system.The Campath-1H antibody is an IgG1 κ form with humanizedvariable and constant regions and CDRs from a ratMAb, Campath-1G.
Alemtuzumab is indicated for the treatment of B-cellchronic lymphocytic leukemia in patients who have beentreated with alkylating agents and who have failed on thistherapy. Alemtuzumab binds to CD52, a nonmodulating antigen that is present on the surface of essentially all B andT lymphocytes; most monocytes, macrophages, and NKcells, and a subpopulation of granulocytes. The proposedmechanism of action is antibody-dependent lysis ofleukemic cells following cell surface binding.

Clinical Use

Treatment of chronic lymphocytic leukaemia (CLL) not totally responsive to other treatment
Induction therapy in renal transplantation
Treatment of relapsing remitting multiple sclerosis (MS)

Drug interactions

Potentially hazardous interactions with other drugs
Other chemotherapy: do not give within 3 weeks of each other.
Live vaccines: avoid for at least 12 months after treatment.

Metabolism

The metabolic pathway of alemtuzumab has not been elucidated. Clearance decreases with repeated administration due to decreased receptor mediated clearance (loss of CD52 receptors in the periphery).

Alemtuzumab Preparation Products And Raw materials

Raw materials

Preparation Products

Less

Alemtuzumab Suppliers

CHINA 61 India 1 United Kingdom 1 United States 5 Global 68

Wuhan Sunrise Technology Development Co., Ltd.

Tel: 27-027-83314682 13554138826
Fax: +86 (27) 8331-4682
Email: whsrtech@vip.163.com
Country: China
ProdList: 246
Advantage: 62

Wuhan Fortuna Chemical Co., Ltd

Tel: 027-59207852 13308628970
Fax: QQ3130921841
Email: buy@fortunachem.com
Country: China
ProdList: 2744
Advantage: 58

Dalian Meilun Biotech Co., Ltd.

Tel: 0411-62910999 13889544652
Email: sales@meilune.com
Country: China
ProdList: 4747
Advantage: 58

Nanjing Sunlida Biological Technology Co., Ltd.

Tel: 025-57798810
Fax: 025-57019371
Email: sales@sunlidabio.com
Country: China
ProdList: 3239
Advantage: 55

Taizhou KEDE Chemical Co., Ltd

Tel: 0576-84613060 13093829633
Fax: 0576-84613060
Email: sales@kedechemical.com
Country: China
ProdList: 299
Advantage: 60

Shanghai Lollane Biological Technology Co.,Ltd.

Tel: 021-52996696，15000506266 15000506266
Fax: +86-21-52996696
Country: China
ProdList: 4768
Advantage: 55

Shanghai EFE Biological Technology Co., Ltd.

Tel: 021-65675885 18964387627
Fax: 021-65675885
Email: info@efebio.com
Country: China
ProdList: 9803
Advantage: 58

Shanghai YuanYe Biotechnology Co., Ltd.

Tel: 021-61312847; 18021002903
Fax: QQ:3008007432
Email: 3008007409@qq.com
Country: China
ProdList: 71826
Advantage: 60

Hefei Hirisun Pharmatech Co., Ltd.

Tel: +86-0551-62678551 +86-15056975894
Fax: 05512678551
Email: sales@hirisunpharm.com
Country: China
ProdList: 176
Advantage: 55

Hefei Hirisun Pharmatech Co., Ltd

Tel: +8615056975894
Fax: 86-0551-62678551
Email: shawn@hirisunpharm.com
Country: CHINA
ProdList: 9911
Advantage: 58

Baoji Guokang Healthchem co.,ltd

Tel: +8615604608665 15604608665
Email: dominicguo@gk-bio.com
Country: CHINA
ProdList: 9414
Advantage: 58

Wuhan Dingtong Pharmaceutical Co., Ltd

Tel: 027-027-59207795 18327179646
Fax: 027-59207795
Email: 18327179646@163.com
Country: China
ProdList: 1986
Advantage: 58

Guangzhou Hongyuan Chemical Co.,Ltd

Tel: 15817493340
Email: 981810490@qq.com
Country: China
ProdList: 1566
Advantage: 58

Jiangsu Greature Bio-Medicine Co., Ltd.

Tel: 0512-85557988 18662338937
Fax: 0512-85557182
Email: frank.wang@greature.com.cn
Country: China
ProdList: 147
Advantage: 58

Wuhan Dingxintong Pharmaceutical Co. , Ltd.

Tel: 15871722230
Fax: 2796190295
Email: 15871722230@163.com
Country: China
ProdList: 4686
Advantage: 58

Wuhan Wiseman Bioengineering Co.,Ltd

Tel: 13419526507 13419526507
Fax: 027-59506022
Email: 13419526507@163.com
Country: China
ProdList: 2845
Advantage: 58

Wuhan Chemstan Biotechnology Co., Ltd.

Tel: 027-65317797 15926423062
Fax: QQ：422450190
Email: 422450190@qq.com
Country: China
ProdList: 10308
Advantage: 58

Hubei Zhongshan Medical Technology Co., Ltd

Tel: 027-61907345 13397111514
Fax: 3443707954
Email: w13397111514@163.com
Country: China
ProdList: 1005
Advantage: 58

Shanghai Minkai Biological Technology Co., Ltd

Tel: 021-021-52919136 17315815539
Email: 2804155403@qq.com
Country: China
ProdList: 180
Advantage: 58